Inhaled sodium cromoglycate to treat cough in advanced lung cancer patients
1996

Inhaled Sodium Cromoglycate for Cough in Lung Cancer Patients

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): M Moroni, C Portal, G Gualtieri, G Nastasil, C Tinelli

Primary Institution: IRCCS Policlinico San Matteo, Universita di Pavia

Hypothesis

Inhaled sodium cromoglycate might be effective in lung cancer patients who presented with irritative neoplastic cough.

Conclusion

Inhaled sodium cromoglycate can significantly reduce cough in non-small-cell lung cancer patients.

Supporting Evidence

  • Cough is a common symptom in lung cancer patients, affecting about 71% of those with unresectable disease.
  • Sodium cromoglycate treatment caused no acute side effects and was well accepted by patients.
  • Cough intensity scores showed a significant reduction in the sodium cromoglycate group compared to placebo.

Takeaway

This study found that a medicine called sodium cromoglycate can help people with lung cancer who have a bad cough.

Methodology

Twenty non-small-cell lung cancer patients were randomized in a double-blind trial to receive either inhaled sodium cromoglycate or placebo, and cough severity was recorded daily.

Limitations

The study had a small sample size, which limits the strength of the conclusions.

Participant Demographics

10 males and 10 females, average age 64.2 years.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication